Imatinib mesylate, as add-on therapy in patients with pulmonary arterial hypertension (PAH) who remain inadequately treated despite receiving at least two PAH-specific drugs, improves exercise capacity and haemodynamics. We evaluated whether 24 weeks of add-on therapy with imatinib compared with placebo also improves right ventricular (RV) function assessed by echocardiography.
Introduction
Pulmonary arterial hypertension (PAH) is associated with significant morbidity and mortality, particularly among patients with poor functional capacity despite disease-specific therapy. 1 Elevated right atrial (RA) pressure, pulmonary vascular resistance (PVR), and low cardiac index (CI) are significant risk factors for increased mortality in these patients. 2 -4 Right ventricular (RV) failure is a key prognostic determinant in PAH. However, due to its complex geometry, RV function is challenging to assess non-invasively by echocardiography. Limited data are available regarding the impact of pharmacologic interventions known to improve exercise capacity, haemodynamics, and functional status on non-invasive echocardiographic measures of RV function. However, novel M-mode and tissue Doppler measures that do not require geometric assumptions regarding RV shape may offer a simplified and widely applicable method to assess RV function in PAH. 5 -7 The echocardiography sub-study of the Imatinib in Pulmonary arterial hypertension (PAH), a Randomized Efficacy Study (IMPRES), was an exploratory sub-study designed to evaluate the hypothesis that among adult patients with significant PAH, treatment with imatinib as an add-on drug will improve echocardiographic measures of RV function to a greater extent than placebo. Specifically, we tested whether 24 weeks of therapy with imatinib compared with placebo were associated with greater improvements in four prospectively selected echocardiographic measures of RV function: tissue Doppler tricuspid annular peak systolic velocity (TA S ′ ), tricuspid annular plane systolic excursion (TAPSE), RV Tei index, and RV fractional area change (RVFAC). We further assessed the impact of imatinib therapy on measures of left ventricular (LV) size, LV systolic function, and LV diastolic function.
Methods

Patient population
The IMPRES trial demonstrated significant improvements in exercise capacity and haemodynamics with imatinib mesylate as add-on therapy compared with placebo. 8 The IMPRES trial enrolled 202 patients at 71 sites in 14 countries on 3 continents. All patients provided written informed consent, which included consent for the echocardiographic analysis. Enrolled patients were at least 18 years of age, diagnosed with Pulmonary Hypertension Group 1, i.e. PAH, with decreased exercise capacity [defined as 6-min walk distance (6MWD) ≤450 m] and a PVR . 800 dynes s/cm 5 despite therapy with two or more PAH-specific medications (endothelin receptor antagonists, phosphodiesterase 5 inhibitors, prostacyclin, or prostacyclin analogues). Patients with a prolonged QTc (.450 ms for males and .470 ms for females), syncope in the prior 3 months, or history of a bleeding disorder were excluded. Patients were randomized 1 : 1 to imatinib or placebo. Participation in the echocardiography sub-study was voluntary and offered to all participating sites. The 27 sites in 8 countries that chose to participate were asked to enroll all patients enrolled in the overall trial at that site (to minimize selection bias). Of 81 patients enrolled in the overall trial at these sites, 74 patients (91%) were also enrolled in the sub-study. For participating sites, echocardiograms were performed by a study-specific protocol at baseline, week-12, and week-24 ( Figure 1 ).
Echocardiographic methods
All sonographers at participating sites underwent central training in the details of the echocardiographic views and techniques at study investigator meetings. Echocardiograms were sent on digital storage media to the core laboratory at the Brigham and Women's Hospital. All quantitative measures on study echocardiograms were performed by a single cardiologist at the core laboratory (P.C.) and independently confirmed by a staff echocardiographer (A.M.S.) with both readers blinded to clinical information and randomized treatment assignment. All measures were performed in triplicate. In accordance with American Society of Echocardiography (ASE) guidelines, 9 TA S ′ was measured using tissue Doppler and TAPSE was measured using M-mode from the lateral tricuspid annulus, RV Tei index was derived from tricuspid regurgitation duration and RV ejection time, and RVFAC was calculated as the percent change in RV cavity area from end-diastole to end-systole in the apical fourchamber view. Peak RV-to-RA systolic gradient was calculated as 4 . [peak tricuspid regurgitation (TR) velocity]. 2 Left ventricular size was expressed as LV chamber area measured in the apical four-chamber view and as LV dimension measured from the parasternal long-axis view. Left ventricular volumes were derived according to the modified biplane Simpson's rule and used to calculate LV ejection fraction (EF) in the standard fashion. 10 Systolic function was also quantified by septal and lateral mitral annular peak systolic velocity. Left ventricular diastolic function was assessed using the mitral annular peak early diastolic velocity (E ′ ), measured from both the lateral and septal aspects of the mitral Figure 1 Disposition of patients in the IMPRES Echocardiographic sub-study. 
Statistical analysis
Continuous variables are presented as means and standard deviations unless otherwise specified. Comparison of baseline clinical and echocardiographic measures between randomized treatment arms was performed using a Fisher's exact test for categorical variables and a t-test for continuous variables. When continuous variables were not normally distributed, comparison was made using the Wilcoxon rank sum test. Two-sided P-values of ,0.05 were considered significant. Sample size was allowed to float. Between-treatment-group differences in the changes in echocardiographic measures from baseline to week-24 were assessed using an ANCOVA with adjustment for the baseline measure using the last observation carried forward (LOCF). Between-treatment-group differences in the change from baseline to week-12, week-12 to week-24, and baseline to week-24 were also assessed using an ANCOVA with adjustment for baseline. In a sensitivity analysis, we repeated the analysis using a mixed-effects repeatedmeasures model which included terms for randomized treatment, visit, treatment-by-visit interaction, and baseline value of the measure of interest as covariates (Supplementary material online, Table S1 ). Where the treatment-by-visit interaction term was not statistically significant, this term was dropped and the treatment term effect estimate and P-value reported. Changes from baseline to week-12 and week-24 were also assessed using the mixed-effects repeated-measures model. Correlation between baseline echocardiographic measures of RV function and baseline haemodynamics, biomarkers, and 6MWD, and between changes in echocardiographic measures and changes in haemodynamics (as assessed by right heart catheterization), biomarkers, and 6MWD at weeks 12 and 24 were assessed by Spearman correlation. All analyses were performed using SAS version 9.2 and Stata version 11.2.
Results
Of 202 patients enrolled in the IMPRES trial, echocardiograms were available in 74 at baseline (37%; 35 placebo, 39 imatinib). Of these patients with baseline echocardiograms, follow-up studies were available in 62 at 12 weeks (84%; 33 placebo, 29 imatinib), and 59 at 24 weeks (80%; 28 placebo, 31 imatinib) (Figure 1) . Compared with IMPRES patients who did not participate in the echocardiography sub-study, patients participating in the echo sub-study were more frequently white (87 vs. 66%, P ¼ 0.002) and more frequently WHO functional class II vs. class III (class II: 35 vs. 19% respectively, class III: 57 vs. 75% respectively; P ¼ 0.03). No significant differences were noted in age, gender, baseline 6MWD, or baseline haemodynamics. Compared with the 59 patients (80% of the 74 enrolled in the sub-study) with baseline echocardiograms who also had week-24 echocardiograms, the 15 patients (20%) who did not were more likely to have prematurely discontinued IMPRES due to an adverse event or a clinical worsening event (2 vs. 27%, P ¼ 0.005); additionally, numerically more deaths (non-significant; 2 vs. 13%, P ¼ 0.10) and PAH-related hospitalizations (non-significant; 10 vs. 27%, P ¼ 0.11) were reported for these 15 patients. Nevertheless, the number of patients without week-24 echocardiographic data was evenly distributed between the placebo and imatinib treatment arms [7 (20%) 
Among patients participating in the echocardiography study, the average age was 50 years old and the majority of patients were female, white, and WHO functional class III. characteristics by treatment group ( Table 1) . A lower baseline PVR was observed in the imatinib group (P ¼ 0.04). At baseline, patients randomized to imatinib had higher TA S ′ , higher TAPSE, higher RV outflow tract time velocity integral (RVOT VTI), larger LV enddiastolic area, and higher mitral annular septal E ′ ( Table 2) . No other differences in baseline echocardiographic measures of RV or LV size or function were observed between treatment groups. Using LOCF, at week-24, patients randomized to imatinib demonstrated greater improvement in RV functional parameters of TA S ′ and RV Tei index compared with patients randomized to placebo ( Table 3) . Imatinib therapy was also associated with reduction in TR jet velocity, increase in RVOT VTI, and decrease in the TR jet velocity/RVOT VTI ratio. No significant between-group differences were apparent in change in right heart size. No between-group differences in resolution of pericardial effusion (P ¼ 0. Table S1 ). Similar findings were observed when analysis was restricted to only patients with measurements at baseline and week-24 (Supplementary material online, Table S2 ) or with patients with measurements at all three study time points (baseline, week-12, and week-24; Supplementary material online, Table S3 ).
For both TA S ′ and RV Tei index, significant improvements were apparent from baseline to week-12 with imatinib compared with placebo ( Figure 2) . The between-group differences in change in both measures from week-12 to week-24 were minimal, suggesting that the majority of the improvement seen at week-24 with imatinib was present by 12 weeks of treatment. Qualitatively similar findings were observed when the analysis was restricted to patients with measurements available at all three time points (Supplementary material online, Table S4 ).
As observed in the overall IMPRES trial, within the echo sub-study imatinib was associated with reduction in PVR and mean pulmonary artery pressure (mPAP), and increase in cardiac index (CI). No difference in median baseline NT-proBNP was noted between treatment groups ( Table 4) . During follow-up, the change in NT-proBNP was correlated with the change in RV Tei index at week-12 (Spearman correlation 0.33, P ¼ 0.04; n ¼ 38) and at week-24 (Spearman correlation 0.43, P ¼ 0.007; n ¼ 39), but not with the other RV functional measures evaluated in the echo substudy. As observed in the overall IMPRES trial, in the echo sub-study imatinib was associated with improvements in 6MWD at week-24 ( Table 4) . None of the RV functional measures correlated with 6MWD at baseline or with the change in 6MWD at week-24.
Discussion
In this echocardiographic sub-study of a multicentre 24-week clinical trial of imatinib as add-on therapy vs. placebo in patients with advanced PAH who remained symptomatic on at least two PAHspecific drugs, imatinib was associated with improvements in RV invasive haemodynamic parameters, imatinib was associated with reduction in peak TR velocity, suggesting decreased pulmonary artery systolic pressure, an increase in the RVOT VTI, a measure related to RV stroke volume, and a decrease in the peak TR velocity to RVOT VTI ratio, a measure that has been correlated with PVR. 11, 12 Supportive of improved RV function and decreased RV afterload, imatinib was associated with increased LV size, reflected in an increase in LV end-diastolic dimension, and an increased LV early diastolic relaxation velocities. These changes in measures of both RV function and LV size and diastolic function were observed at the week-12 assessment, and persisted without significant change at week-24. Right ventricular failure is associated with increased risk of mortality in PAH. 1, 3 Right ventricular function may continue to decline despite effective reduction in PVR in a subset of PAH patients, and these patients experience poor prognosis despite reduced PVR. The complex geometry of the RV, which is further distorted by hypertrophy and enlargement with progressive RV pressure overload, makes non-invasive assessment of RV function by echocardiography challenging. Indeed, RVFAC, an established risk factor for adverse outcomes in patients with LV dysfunction, 14, 15 has not been consistently related to risk for adverse outcomes in PAH. 16 -18 As in our study, prior clinical trials of pharmacotherapy known to improve exercise capacity and haemodynamics in PAH have not reliably detected associated improvements in RVFAC. 5, 6 Instead, indirect markers of RV overload-such as degree of septal flattening quantified by the LV eccentricity index and the presence of a pericardial effusion-have been more consistently associated with increased risk of death. 16 -19 Given the prominent contribution of longitudinal shortening to RV ejection, measures of RV systolic longitudinal displacement (TAPSE) and rate of displacement (TA S ′ ) offer simplified measures of RV systolic function that do not rely on geometric assumptions of RV shape. 20 TA S ′ has been shown to correlate significantly with RV ejection fraction by MRI 21 -23 and with mPAP and PVR 24 in heart failure and in chronic thromboemblic pulmonary embolism. To our knowledge, our study is the first to assess the impact of a PAH-specific drug shown to improve haemodynamics on these novel parameters of RV function. We observed significant improvement in TA S ′ , in addition to septal S ′ , with imatinib therapy. Baseline TA S ′ correlated with baseline mPAP and PVR, and the improvement in TA S ′ significantly correlated with the decrease in mPAP measured invasively.
We did not observe a significant improvement in TAPSE (P ¼ 0.08). While reduced TAPSE is associated with increased risk of death in PAH, 16, 18, 25 TAPSE has not been assessed in interventional studies in pulmonary hypertension. 5 -7 Therefore, the responsiveness of TAPSE to change in PVR and RV systolic function is not well established. The angle dependency of TAPSE in addition to the relatively small degrees of excursion being measured may limit its sensitivity. In addition, TAPSE may be significantly affected by LV apical motion, such that an undefiled and hyperdynamic LV may increase cardiac rocking and the TAPSE value. 26 Relief of pulmonary vascular obstruction with improved LV filling may paradoxically result in lower TAPSE due to less hyperdynamic LV function and diminished rocking. The RV Tei index is a Doppler-based measure of combined RV systolic and diastolic performance. Multiple studies have demonstrated a relationship between RV Tei index and risk of death in PAH 18, 27, 28 and improvement in RV Tei index with therapies that improve haemodynamics. 6, 7 In our study, imatinib was similarly associated with significant improvements in RV Tei index. Possibly because it integrates information regarding both RV systolic and diastolic function, the change in RV Tei index demonstrated the strongest correlation with the changes in invasive haemodynamic parameters (PVR, CI) and NT-proBNP among the echocardiographic measures of RV function assessed. The observed increase in LV size with imatinib likely reflects improved LV filling as a result of reduced PVR and improved RV function. Interestingly, we also observed significant improvement in LV early diastolic relaxation velocity with imatinib. This may be a result of increased LV filling. Alternatively, PAH has been associated with impairments in LV diastolic function, possibly as a result of the markedly enlarged RV adversely affecting ventricular coupling. 29 -31 However, to our knowledge, the concurrent improvements in haemodynamics, RV function, and LV diastolic function have not been previously described, particularly with the use of relatively novel parameters of diastolic function such as TDI mitral annular E ′ .
We are unable to quantify the relative contribution of afterload reduction vs. improved 'intrinsic' chamber function to the observed improvements in structural and functional measures associated with imatinib. Changes in TA S ′ and RV Tei index correlated with changes in haemodynamic measures, suggesting a contribution of reduced afterload to the improvements noted in these measures. However, the correlations of RV functional measures with invasive haemodynamics were generally modest in magnitude, suggesting that alterations in load alone cannot fully account for the observed changes in RV functional measures. Other novel measures of RV function that may be less load-dependent, such as strain or strain rate, were not prospectively evaluated in this study as methods for their measurement were not well established at the time of study design.
This study has several limitations. Only a subset of patients enrolled in the overall trial participated in the echocardiography sub-study, potentially limiting the generalizability of our findings. However, among participating sites in the echo sub-study, 91% of patients enrolled in the overall trial were also enrolled in the substudy, suggesting minimal selection bias at participating sites. In addition, patients in the sub-study were comparable with those not in the sub-study with regards to baseline 6MWD and haemodynamics, although a higher proportion of patients in the echo sub-study were white and WHO functional class II vs. class III. Fifteen of the 74 (20%) patients in the sub-study had missing echocardiographic data at week-24, although the numbers of patients without any follow-up echo data were evenly distributed between treatment arms. We addressed missing data by using a LOCF analysis, which is often considered to be more conservative than an observed case analysis. 32, 33 The validity of our approach is supported by two additional findings. First, the majority of the changes observed in both TA S ′ and RV Tei index between treatment arms occurred by week-12 with minimal changes between week-12 and week-24. Second, performing the analysis using an observed case analysis (i.e. only individuals with values available at both baseline and week-24) produced similar results. Patients in the sub-study randomized to imatinib demonstrated higher TA S ′ , TAPSE, RVOT VTI, septal E ′ , and larger LV enddiastolic area, suggesting better RV function at baseline in the imatinib group. To mitigate the impact of these differences in baseline values, we employed an ANCOVA which adjusts for the baseline value in determining the significance of the between-group differences in the changes in echo measures. Despite these limitations, this remains a sizeable echocardiographic study in PAH. All studies were performed by a uniform prespecified echo protocol and analysed by a single blinded cardiologist at a core laboratory with good intra-observer repeatability. To our knowledge, this is the largest study to assess the impact of this novel agent in PAH on RV function, and the only randomized study in PAH to investigate the impact of a pharmacologic intervention on TA S ′ , TAPSE, and LV relaxation patterns using tissue Doppler imaging. These findings suggest that echocardiography can be effectively utilized to detect treatment-associated improvement in RV function in PAH trials. Additional studies, assessing the prognostic implications of changes in RV measures with intervention, are needed to determine the incremental value of these measures in therapeutic trials and clinical practice.
Conclusions
Among patients with advanced PAH who remained symptomatic despite treatment with at least two PAH-specific drugs, treatment with imatinib as an add-on drug compared with placebo is associated . with significant improvements in echocardiographic Doppler and tissue Doppler measures of RV function, with associated improvements in LV size and LV early diastolic relaxation. These findings suggest that imatinib may be effective at attenuating the haemodynamic and the cardiac structural and functional changes associated with PAH. Further study is warranted to assess whether the observed changes in these non-invasive measures of RV function are prognostic for outcomes in PAH.
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